Hematology Times
|
MyelomaCRd elicits responses in relapsed/refractory MM
Session at ASCO 2013
Credit: ASCO/Scott Morgan Combination carfilzomib, lenalidomide, and dexamethasone (CRd) can produce rapid responses in patients with relapsed or refractory multiple myeloma (MM), even those who are refractory to lenalidomide, results of a phase 1b/2 study suggest. Although the responses were considered durable—lasting a median of 18.8 months—nearly half of patients ultimately discontinued the treatment due to disease progression. Michael Wang, MD, of MD Anderson Cancer Center in Houston . . . [Read Article] Updated results reveal ‘new standard of care’ for relapsed/refractory MM
Audience at ASCO 2013
Credit: ASCO/Scott Morgan New data suggest pomalidomide plus low-dose dexamethasone (POM-LoDEX) should be the standard of care for patients with relapsed or refractory multiple myeloma (MM), according to a speaker at the 2013 ASCO Annual Meeting. Updated results of the phase 3 MM-003 trial showed that, with longer follow-up, POM-LoDEX still conferred a survival advantage over high-dose dexamethasone (HiDEX). And patients experienced the benefit of POM-LoDEX whether or not they were refractory . . . [Read Article] Risk of hematologic, other cancers after CT scans
Patient undergoing a CT scan
Credit: Angela Mary Butler A large, population-based study has provided additional insight into the risk of hematologic and solid tumor malignancies associated with CT scans. Previous research has suggested CT scans pose cancer risks, particularly following exposures in childhood. However, most studies have estimated risks indirectly, and some radiation experts have questioned the validity of these estimates. To provide more definitive data, John D. Mathews, MD, PhD, of the University of Melbourne in Australia . . . [Read Article] Depression linked to early death in cancer survivors
Sad woman
Credit: Jiri Hodan In a large study, depressed cancer survivors were twice as likely to die prematurely as those who did not suffer from depression. The study covered a number of malignancies, including lymphoma and multiple myeloma, but the risk of death proved to be independent of cancer type. Floortje Mols, PhD, of Tilburg University in The Netherlands, and her colleagues conducted this research and described the results in Journal of Cancer Survivorship. [Read Article] Protein complex may play a role in hematologic and other cancers
Multiple myeloma cells
Researchers have identified a group of proteins that are mutated in about one-fifth of all human cancers. The proteins are members of the BAF complex, which affects how DNA is packaged in cells. The group’s findings suggest the proteins work to suppress the development of a number of cancers, including leukemias, lymphomas, and multiple myeloma. And mutations in the BAF complex have wide-ranging effects that rival those of the tumor suppressor p53. [Read Article] |
|